Fulltext

Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis

Stucki, Armin ; Cottagnoud, Marianne ; Acosta, Fernando ; Egerman, Ueli ; Laeuffer, Jörg M. ; Cottagnoud, Philippe

In: Journal of Antimicrobial Chemotherapy, 2012, vol. 67, no. 3, p. 661-665

Ajouter à la liste personnelle
    Titre
    • Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis
    Auteur
    • Stucki, Armin. Clinic for Pneumology and Rehabilitation, Heiligenschwendi, Switzerland
    • Cottagnoud, Marianne. Clinic for Internal Medicine, Spital Netz Bern Ziegler, Bern, Switzerland
    • Acosta, Fernando. Clinic for Internal Medicine, Spital Netz Bern Ziegler, Bern, Switzerland
    • Egerman, Ueli. Clinic for Internal Medicine, Inselspital, Bern, Switzerland
    • Laeuffer, Jörg M.. Janssen EMA, Baar, Switzerland
    • Cottagnoud, Philippe. Clinic for Internal Medicine, Klinik Sonnenhof, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Antimicrobial Chemotherapy, 2012, vol. 67, no. 3, p. 661-665. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:304594
    Summary
    Objectives In this study the efficacy of doripenem, a new broad-spectrum carbapenem, was tested against an Escherichia coli strain and a Klebsiella pneumoniae strain in an experimental animal model. The comparator was cefepime monotherapy. Methods The rabbit meningitis model was used in this study and the penetration of doripenem through uninflamed and inflamed meninges was determined. Results Doripenem, injected three times (75 mg/kg), led to serum peak levels around 100 mg/L and trough levels around 5 mg/L, resulting in a penetration rate of 14% through inflamed meninges and 7% through uninflamed meninges. Against K. pneumoniae, doripenem was slightly but not significantly more efficacious than cefepime over 8 h (5.40 ± 1.37 log10 cfu/mL versus 3.59 ± 0.89 log10 cfu/mL for cefepime). Also against the E. coli strain doripenem was slightly superior to the comparator (5.55 ± 0.87 log10 cfu/mL versus 3.80 ± 1.10 log10 cfu/mL for cefepime), although the difference was not significant. Conclusions Doripenem is a potential monotherapy for the treatment of meningitis due to Gram-negative microorganisms